Insmed Delivers Rare Disappointment as Brinsupri Flops in Mid-Stage Rhinosinusitis Study on December 19, 2025 acquisition brensocatib Brinsupri Chronic sinusitis DPP1 inhibitor Insmed mid-stage trial Nasal inflammation Nasal Polyps stocks trial failure +
Insmed Secures FDA Approval for First DPP1 Inhibitor in Lung Disease on August 13, 2025 Approved brensocatib Brinsupri Bronchiectasis CTSC gene Inhibitor Insmed Lung diseases United States Food and Drug Administration +
Insmed's Brinsupri Receives First-Ever FDA Approval for Progressive Lung Disease on August 13, 2025 Approved brensocatib Brinsupri Bronchiectasis CTSC gene Inhibitor Insmed Lung diseases neutrophil-mediated disease non-cystic fibrosis bronchiectasis Progressive United States Food and Drug Administration +